Try these: Panado Ivedal Zometa Zofaril

Vsiqq 120 mg/mL Solution for injection

PDF Leaflet Revision Date: 15 May 2025

API: Brolucizumab | Company: Novartis South Africa

Clinical Summary

Quick overview from the medicine insert

Indication

Treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema.

Dosage (summary)

6 mg (0.05 mL) by intravitreal injection; Wet AMD: every 4 weeks for 3 doses, then every 12 weeks; DME: every 6 weeks for 5 doses, then every 12 or 16 weeks.

Special Populations

Hepatic impairment
Renal impairment
Elderly (u2265 65 years)

Pregnancy & Breastfeeding

Not recommended during pregnancy or breastfeeding due to potential risks.

Contraindications

Hypersensitivity to brolucizumab
Active ocular infections
Active intraocular inflammation

Common side effects

Reduced visual acuity
Cataract
Conjunctival haemorrhage
Vitreous floaters

Counselling Points

Use effective contraception during treatment and for 1 month after
Monitor for visual disturbances post-injection
Report any symptoms of intraocular inflammation immediately

Serious warnings

Risk of endophthalmitis
Retinal detachment
Transient increases in intraocular pressure

On This Page